flutamide for Prostate Cancer
This study is evaluating whether radiation therapy is more effective than radiation therapy given together with androgen-deprivation therapy in treating patients with prostate cancer.
See full descriptionAbout the trial for Prostate Cancer
Treatment Groups
This trial involves 2 different treatments. Flutamide is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
About The Treatment
Eligibility
This trial is for male patients aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether flutamide will improve 1 primary outcome and 15 secondary outcomes in patients with Prostate Cancer. Measurement will happen over the course of From the date of randomization to the date of death due to any cause..
Patient Q & A Section
How does flutamide work?
Findings from a recent study suggest that the mechanism of action of antiandrogens is complex, but that specific inhibition of AR signaling may override the more general effects of androgens in prostate carcinogenesis.
What are common treatments for prostate cancer?
As treatment options for prostate cancer have improved over the last 25 years due to increased awareness, education and treatment, most patients are now able to choose to receive a variety of management options, including surgery, radiation therapy and some newer medication based treatments. These options make prostate cancer a very treatable disease.
What is prostate cancer?
Prostate is the most common cancer in males. The American Cancer Society estimates that there will be more than 178,000 new cases and more than 68,000 related deaths per year in the US in 2019. Prostate cancer is classified based on the Gleason scoring system as well as the percentage of cancer in the prostate. The lower the percentage of cancer in the prostate and the lower the Gleason score, the lower the risk for prostate cancer.
What are the signs of prostate cancer?
Prostate cancer is not a rare disease that has many common signs and symptoms; it is more likely to be diagnosed after it has already metastasized.
Can prostate cancer be cured?
Men and women and many healthcare professionals hold the belief that cancer can be cured, even when there is significant evidence of the contrary. Data from a recent study is a first step in understanding the factors associated with a belief that cancer can be cured. Data from a recent study suggest that many doctors and patients, particularly in the context of [advanced prostate cancer](https://www.withpower.com/clinical-trials/advanced-prostate-cancer), are more likely to interpret symptoms as signs of an underlying progressive disease if they also expect a cure will be achieved. Understanding the belief that cancer can be cured, and the factors associated with this belief, will help us design effective and informative treatment for people with prostate cancer.
How many people get prostate cancer a year in the United States?
The US Preventive Cervical Cancer Task Force (2009) identified the need to more fully characterize the burden of PCa and its natural history to guide its prevention, including the development of recommendations to minimize the number of men at high risk for PCa. A detailed review is required to characterize the burden of PCa and the natural history of this disease, including disease and death from PCa and causes of PCa in males.
What causes prostate cancer?
A number of rare alleles at several well-studied loci were identified that may increase the risk of prostate cancer. Other genes or loci that could be causal agents have yet to be discovered.
Is flutamide typically used in combination with any other treatments?
Testicular cancer is not only treated with or without orchiectomy. It must be kept in mind when evaluating flutamide therapy in terms of oncological outcomes.
What is the average age someone gets prostate cancer?
Prostate cancer typically presents as a slow-growing prostate cancer in patients who have experienced prostatic enlargement that occurs at an average age of 72 years.
What are the chances of developing prostate cancer?
Results from a recent clinical trial indicates that approximately one in 6 men in the general population have BPH. Of these men, approximately one in 9 will develop prostate cancer with approximately 70 in 1 million men at risk from prostate cancer. The likelihood of developing prostate cancer increases with age, and the five-year risks for Caucasian, African American or Hispanic men is in the range of 9.5%-16.9% and 8.0%-17.2%, respectively.
Have there been other clinical trials involving flutamide?
Results from a recent paper of the meta-analysis indicates that the two existing randomized, placebo-controlled clinical trials and one observational study evaluating the efficacy of flutamide in the treatment of prostate cancer could not find a statistically significant superiority of flutamide compared to placebo. There appears to be no compelling rationale for the use of flutamide as treatment in prostate cancer. More trials examining the efficacy of flutamide are necessary.
How quickly does prostate cancer spread?
Findings from a recent study of this study are very encouraging for the detection of the spread of prostate cancer. Despite the PSA group presenting an increase in the incidence of metastatic disease, in patients that had a Gleason score of 7 to 10 the risk group was undetectable. This demonstrates the ability of PSA to detect early spread of prostate cancer and the need for alternative markers of the disease to be used.